CG Oncology Inc. (CGON) vs GRAIL Inc. (GRAL)
A side-by-side comparison of CG Oncology Inc. and GRAIL Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CGON
CG Oncology Inc.
$66.11HealthcareDelayed quote: Oct 6, 2026, 11:25 AM EDT
GRAL
GRAIL Inc.
$140.99HealthcareDelayed quote: Oct 6, 2026, 11:25 AM EDT
Total return — CGON vs GRAL
growth of $100 · dividends reinvested · last 2yCGON +93.5% (+39.1%/yr)GRAL +1028.0% (+235.9%/yr)GRAL compounded faster over this window
Log scale — wide-divergence pair
CGON GRAL
CGON vs GRAL: by the numbers
- •GRAL is the larger company ($6.05B vs $5.83B market cap).
- •Both run net losses; GRAL's is the smaller (-236.95% vs -3602.68% net margin).
Metrics side by side
Valuation
| Metric | CGON | GRAL |
|---|---|---|
| P/S ratio | 936.27 | 36.61 |
| P/B ratio | 5.67 | 2.38 |
Profitability
| Metric | CGON | GRAL |
|---|---|---|
| Gross margin | -15.02% | -42.52% |
| Operating margin | -4722.13% | -362.95% |
| Net margin | -3602.68% | -236.95% |
| ROE | -21.80% | -15.40% |
| ROIC | -24.33% | -20.26% |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.